Novel (New) Oral Anticoagulants (NOACs)
1. Utilize a systematic process of care, including initiation and assessment of therapy and dosing adjustments, to optimize effectiveness and minimize adverse effects of patients taking warfarin.
2. Consider new agents in patients with atrial fibrillation and at least one other risk factor for stroke that do not require frequent laboratory monitoring and are as effective as warfarin for prevention of stroke or systemic embolism and have comparable risks of major bleeding.
3. Develop collaborative care plans with patient education to counsel patients on safe and effective self-administration of anticoagulants, emphasizing self-monitoring to prevent complications.
4. Establish or revise existing practice-level protocols for anticoagulation management, based on current evidence-based recommendations and guidelines, including having clearly defined staff roles and responsibilities.
View technical requirements (opens in a new window).
View CME credit information (opens in a new window).
View AAFP staff list (opens in a new window).
View disclosures and disclaimers (opens in a new window).
All materials herein are protected by copyright and are for the sole, personal use of the purchaser. No part of the written, oral, and broadcast production may be copied, duplicated, replicated or retransmitted without the prior permission of the applicable copyright owner.
The unauthorized reproduction or distribution of a copyrighted work is illegal. Criminal copyright infringement, including infringement without monetary gain, is investigated by the FBI and is punishable by up to five years in federal prison and a fine of $250,000.
Robert Dachs, MD, FAAFP, Vice-Chairman, Department of Emergency Medicine, Ellis Hospital, Schenectady, New York; Clinical Associate Professor and Director of Research, Ellis Hospital Family Medicine
- 1.00 AAFP prescribed